title: Promise and challenges in drug discovery and development of hybrid anticancer drugs.
abstract: BACKGROUND
  Because cancer is a complex disease, it is unlikely that a single mono functional 'targeted' drug will be effective for treating this most advanced disease. Combined drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in cancer treatment. In order to improve the efficiency of using a two-drug cocktail, one approach involves the use of the so-called hybrid drugs, which comprises the incorporation of two drugs in a single molecule with the intention of exerting dual drug action.
  
  
  OBJECTIVE
  In the present article, we discuss the design, synthesis and various applications of anticancer hybrid agents and the developments in this field during the last few decades. Additionally, we describe different types of linkers and their role in contributing towards biological effects and the in vivo mechanism of drug release. We also depict some challenges from scientific and regulatory perspectives in the hybrid drug development process.
  
  
  CONCLUSIONS
  In the era of increasing drug resistance in cancer patients, the discovery of hybrid drugs could provide an effective strategy to create chemical entities likely to be more efficacious and less prone to resistance. However, some technical and regulatory challenges will have to be surmounted before hybrid drugs succeed in the clinical settings and justify the considerable promise of this novel concept.
authors.affiliation: Research Instructor, Thomas Jefferson University, Jefferson School of Pharmacy, Department of Pharmaceutical Sciences, 130 South 9th Street, Edison Building, Suite 1510 F, Philadelphia, PA 19107, USA.
authors.forename: Lalji K
authors.initials: LK
authors.lastname: Gediya
authors.forename: Vincent Co
authors.initials: VC
authors.lastname: Njar